Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
RB+/− individuals develop retinoblastoma and, subsequently, many other tumors. The Rb relatives p107 and p130 protect the tumor-resistant Rb−/− mouse retina. Determining the mechanism underlying this tumor suppressor function may expose novel strategies to block Rb pathway cancers. p107/p130 are best known as E2f inhibitors, but here we implicate E2f-independent Cdk2 inhibition as the critical p107 tumor suppressor function in vivo. Like p107 loss, deleting p27 or inactivating its Cdk inhibitor (CKI) function (p27CK−) cooperated with Rb loss to induce retinoblastoma. Genetically, p107 behaved like a CKI because inactivating Rb and one allele each of p27 and p107 was tumorigenic. Although Rb loss induced canonical E2f targets, unexpectedly p107 loss did not further induce these genes, but instead caused post-transcriptional Skp2 induction and Cdk2 activation. Strikingly, Cdk2 activity correlated with tumor penetrance across all the retinoblastoma models. Therefore, Rb restrains E2f, but p107 inhibits cross talk to Cdk. While removing either E2f2 or E2f3 genes had little effect, removing only one E2f1 allele blocked tumorigenesis. More importantly, exposing retinoblastoma-prone fetuses to small molecule inhibitors of E2f (HLM006474) or Cdk (R547) for merely 1 week dramatically inhibited subsequent tumorigenesis in adult mice. Protection was achieved without disrupting normal proliferation. Thus, exquisite sensitivity of the cell-of-origin to E2f and Cdk activity can be exploited to prevent Rb pathway-induced cancer in vivo without perturbing normal cell division. These data suggest that E2f inhibitors, never before tested in vivo, or CKIs, largely disappointing as therapeutics, may be effective preventive agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957 · cited 2×
“Cdk2 fires replication origins, and feeds back to promote E2f activity by phosphorylating Rb family proteins (9).”
The E2F transcriptional network: old acquaintances with new faces
Dimova, D. K., & Dyson, N. J. (2005) · Oncogene · doi:10.1038/sj.onc.1208612 · Cited by 715
Pocket proteins and cell cycle control
Cobrinik, D. (2005) · Oncogene · doi:10.1038/sj.onc.1208619 · Cited by 601
Hurford, R. K., Cobrinik, D., Lee, M. H., & Dyson, N. (1997) · Genes & Development · doi:10.1101/gad.11.11.1447 · Cited by 431
Dissecting the Unique Role of the Retinoblastoma Tumor Suppressor during Cellular Senescence
Chicas, A., Wang, X., Zhang, C., McCurrach, M., Zhao, Z., Mert, O., Dickins, R. A., Narita, M., Zhang, M., & Lowe, S. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.023 · Cited by 388 · cited 2×
“Notably, Rb, but not p107/p130, inhibits E2f target expression during senescence (36), again mimicking our findings in terminally differentiating retinal neurons.”
Tsai, K. Y., Hu, Y., Macleod, K. F., Crowley, D., Yamasaki, L., & Jacks, T. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80274-9 · Cited by 372
Chen, D., Livne-bar, I., Vanderluit, J. L., Slack, R. S., Agochiya, M., & Bremner, R. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.025 · Cited by 281
Self-citationCell type-specific effects of Rb deletion in the murine retina
MacPherson, D., Sage, J., Kim, T., Ho, D., McLaughlin, M. E., & Jacks, T. (2004) · Genes & Development · doi:10.1101/gad.1203304 · Cited by 222
Ziebold, U., Reza, T., Caron, A., & Lees, J. A. (2001) · Genes & Development · doi:10.1101/gad.858801 · Cited by 200
Binné, U. K., Classon, M. K., Dick, F. A., Wei, W., Rape, M., Kaelin, W. G., Näär, A. M., & Dyson, N. J. (2007) · Nature Cell Biology · doi:10.1038/ncb1532 · Cited by 175 · cited 3×
“For example, by preventing Rb family phosphorylation, CKIs inhibit Cdk2-mediated activation of E2f.”
Cited by
The broken cycle: E2F dysfunction in cancer
Kent, L. N., & Leone, G. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 800
Dimaras, H., Corson, T. W., Cobrinik, D., White, A., Zhao, J., Munier, F. L., Abramson, D. H., Shields, C. L., Chantada, G. L., Njuguna, F., et al. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.21 · Cited by 553
RB1: a prototype tumor suppressor and an enigma
Dyson, N. J. (2016) · Genes & Development · doi:10.1101/gad.282145.116 · Cited by 435
Lu, Y., Shiau, F., Yi, W., Lu, S., Wu, Q., Pearson, J. D., Kallman, A., Zhong, S., Hoang, T., Zuo, Z., et al. (2020) · Developmental Cell · doi:10.1016/j.devcel.2020.04.009 · Cited by 291
Self-citationHenley, S. A., & Dick, F. A. (2012) · Cell Division · doi:10.1186/1747-1028-7-10 · Cited by 281
Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01
Pascual-Pasto, G., Bazan-Peregrino, M., Olaciregui, N. G., Restrepo-Perdomo, C. A., Mato-Berciano, A., Ottaviani, D., Weber, K., Correa, G., Paco, S., Vila-Ubach, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat9321 · Cited by 118
Singh, H. P., Wang, S., Stachelek, K., Lee, S., Reid, M. W., Thornton, M. E., Craft, C. M., Grubbs, B. H., & Cobrinik, D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808903115 · Cited by 78
Okuma, A., Hanyu, A., Watanabe, S., & Hara, E. (2017) · Nature Communications · doi:10.1038/s41467-017-02281-x · Cited by 69
Metadata
- Authors
- Sangwan, M., McCurdy, S. R., Livne-bar, I., Ahmad, M., Wrana, J. L., Chen, D., & Bremner, R.
- Venue
- Oncogene
- Published
- 2012-01-30
- Volume
- 31
- Issue
- 48
- Pages
- 5019-5028
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2015891530
- Cited by
- 66
- References
- 15
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.